Currently tracking 36 active AI roles, up 67% versus the prior 4 weeks. Primary focus: Agent · Engineering. Salary range $58k–$345k (avg $175k).
| Title | Stage | AI score |
|---|---|---|
| Sr. Director (Medical) Oral Therapies This role is for a Sr. Director (Medical) Oral Therapies at Eli Lilly, focusing on medical affairs and clinical research. The position involves strategic planning for launch and commercialization activities, supporting local clinical trials, managing adverse event reporting, reviewing protocols and publications, and interacting with regulatory and reimbursement agencies. The role requires scientific and medical expertise to support marketed products and potentially early-phase trials, ensuring all activities comply with regulations and company standards. | — | 0 |
| Medical Science Liaison – Cardiometabolic Health This role is for a Medical Science Liaison in Cardiometabolic Health at Eli Lilly. The primary responsibilities include scientific engagement and education with healthcare professionals, managing relationships with Key Opinion Leaders (KOLs), generating insights from therapeutic trends, collaborating cross-functionally, and ensuring compliance with regulations. The role requires a strong scientific background, excellent communication skills, and the ability to travel. | — |
| 0 |
| Director Medico Neurología Mexico This role is for a Clinical Research Physician (CRP) in Medical Affairs at Eli Lilly, focusing on strategic planning for launch and commercialization activities to meet patient needs. The CRP will contribute to global and regional clinical/medical plans, oversee local clinical trials, report adverse events, review protocols and publications, and support pricing, reimbursement, and access (PRA) initiatives. The role also involves engaging with external clinical customers and thought leaders, and ensuring compliance with regulations and company standards. The CRP acts as a scientific resource and provides expert medical support for marketed products and new drug submissions. | — | 0 |